The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine
Science Advances · 24.10.2025 · 11 (43)
DOI: 10.1126/sciadv.adx1576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Advances, erschienen am 24.10.2025. Verfasst von Helen Forgham und 15 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute of Bioengineering & Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia. Hauptthemen laut MEDLINE: Nanomedicine, Neoplasms, Nanostructures. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The nanomedicine field continues to gain momentum, with several groundbreaking clinical trials underway. However, despite the promise of advanced antifouling nanoparticles incorporating poly(ethylene glycol)—a key component in the development of COVID-19 vaccines—the clinical translation of nanomedicine remains limited. This is primarily due to the relatively low delivery efficacy, with passive targeting relying on the enhanced permeability and retention effect, and active targeting leading to only modest improvements in target tissue accumulation. Improving the targeting, biocompatibility, and functionality of nanoparticles has the potential to create more effective, personalized, and minimally invasive therapies. This review aims to highlight the rise of a previously unidentified order of immune-minded nanomaterials and explores how mechanobiological principles and biomechanical nanotools are revolutionizing our understanding of nano-bio interactions in relation to disease. By considering mechanical properties such as stiffness, surface topology, and behavior under physiological flow conditions, researchers can better engineer nanoparticles for improved therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Australian Institute of Bioengineering & Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia.
- School of Biomedical Engineering, Faculty of Engineering, The University of Sydney, Darlington, NSW, 2008, Australia.
- Center for Nanomedicine and Department of Anaesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Centre for Advanced Imaging (CAI), ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, St. Lucia, Queensland 4072, Australia.
- Institute of Biopharmaceutical and Health Engineering (iBHE), Tsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen 518055, China.
- Division of Materials Science and Engineering, Boston University, Boston, MA, USA.
ORCID-Profile: Helen Forgham, Jiayuan Zhu, Liwei Liu, Heather Biggs, Aleksandr Kakinen, Yuhao Jiang, Xinru You, Kristofer J Thurecht, Shaohua Ma, Lining Arnold Ju, Wei Tao, Thomas P Davis, Joyce Y Wong, Ruirui Qiao
Zitieren
APA
Forgham, H., Chang, Y., Wang, Y., Zhu, J., Liu, L., Biggs, H., Kakinen, A., Jiang, Y., You, X., Thurecht, K. J., Ma, S., Ju, L. A., Tao, W., Davis, T. P., Wong, J. Y., & Qiao, R. (2025). The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine. Science Advances, 11(43). https://doi.org/10.1126/sciadv.adx1576
Vancouver
Forgham H, Chang Y, Wang Y, Zhu J, Liu L, Biggs H, et al. The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine. Science Advances. 2025;11(43). doi:10.1126/sciadv.adx1576
BibTeX
@article{Forgham2025,
author = {Forgham, Helen and Chang, Yixin and Wang, Yao and Zhu, Jiayuan and Liu, Liwei and Biggs, Heather and Kakinen, Aleksandr and Jiang, Yuhao and You, Xinru and Thurecht, Kristofer J and Ma, Shaohua and Ju, Lining Arnold and Tao, Wei and Davis, Thomas P and Wong, Joyce Y and Qiao, Ruirui},
title = {The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {43},
doi = {10.1126/sciadv.adx1576}
}
EUVIMED